CLTC and renal carcinoma: In addition to lung cancer, ALK has further been found to generate fusions in ALCL (fused to NPM, TPM3, TPM4, ATIC, TFG, CLTC, MSN, MYH9, or ALO17) [1], [2], [12], [13], [14], [15], [16], [17], [18], [19], IMT (TPM3, TPM4, CLTC, CARS, RANBP2, ATIC, or SEC31A) [19], [20], [21], [22], [23], [24], ALK-positive large B-cell lymphoma (CLTC, NPM, SEC31A, or SQSTM1) [25], [26], [27], [28], and renal cancer (VCL, TPM3 or EML4) (Table 1) [29], [30].